Tela Bio Exceeds $20M Revenue in Q2 2025, Reiterates $85M-$88M 2025 Target Amid International Expansion

Tela Bio reiterated its 2025 revenue target of $85M-$88M, citing acceleration in international expansion. Q2 2025 saw the first quarter to exceed $20M in revenue, with the highest global unit sales across all products.

TELA Bio, Inc. (TELA) has reiterated its 2025 revenue target of $85 million to $88 million, reflecting acceleration in international expansion. The company reported its second quarter (Q2) 2025 results, with revenue exceeding $20 million for the first time, driven by the highest global unit sales across all products [1].

The Q2 2025 revenue increased by 26% year-over-year, reaching $20.2 million. Revenue from OviTex grew by 12%, while OviTex PRS revenue surged by 53%. Gross margin improved to 69.8% from 68.8% in the prior year period. The company ended the quarter with $35 million in cash and cash equivalents [2].

CEO Antony Koblish highlighted the strong performance, stating, "Q2 2025 was the first quarter to exceed $20 million in revenue, stemming from the highest global unit sales in the quarter across all product categories." The company's international sales grew by 25% over Q2 last year, with European sales contributing significantly to this growth [2].

TELA Bio has expanded its European market presence with a new product launch and secured a 4-year framework agreement with the National Health Service (NHS) in England. The company has also appointed Jeff Blizzard as President, who brings extensive European market experience and a track record of delivering predictable growth [2].

The company's focus on enhanced territory management and a patient-centric commercial strategy is expected to drive future growth. TELA Bio aims to achieve its full-year 2025 guidance of $85 million to $88 million, representing a 23% to 27% year-over-year growth [2].

Analysts maintain a neutral to slightly positive tone, with the current average analyst rating on the shares being "buy." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXBE3528:0-tela-bio-misses-q2-revenue-estimates/
[2] https://seekingalpha.com/news/4483591-tela-bio-reiterates-85m-88m-2025-revenue-target-as-international-expansion-accelerates